HCP Live July 26, 2024
Gus Alva, MD

In this part of our 5-part series, Gus Alva, MD discusses the next steps in research for long-term effects and broader applications of MDMA-assisted therapy.

As August 11, 2024 approaches, the psychiatric community, and public health as a whole, wait with anticipation surrounding the US Food and Drug Administration’s decision on 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy in the management of posttraumatic stress disorder (PTSD).

A subject mired in controversy as a result of decades-old stigma, MDMA-assisted therapy has, with extensive research efforts and clinical trial data, proven its potential. Beyond MDMA-assisted therapies, clinical programs and trials for other psychedelic agents, including psilocybin, ketamine, and other compounds, have furthered discussions around the roles of these therapeutic options in psychiatric care.

Backed by positive...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Conferences / Podcast, Mental Health, Provider, Trends
Why a former Ascension exec became CEO of a mental health organization
When Treating Obesity, Don’t Forget the Mental Health Angle
New York state to implement new mental health parity requirements: 3 notes
7 state behavioral health policy updates
Substance Use Disorder Screening Must Be Part Of Cancer Care

Share This Article